Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 68580

1.

Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects.

Li J, Wu Y, Wang D, Zou L, Fu C, Zhang J, Pak-Heng Leung G.

Pharmacol Res. 2019 Jun 13:104313. doi: 10.1016/j.phrs.2019.104313. [Epub ahead of print]

PMID:
31202781
2.

Designed P-glycoprotein inhibitors with triazol-tetrahydroisoquinoline-core increase doxorubicin-induced mortality in multidrug resistant K562/A02 cells.

Kairuki M, Qiu Q, Pan M, Li Q, Zhou J, Ghaleb H, Huang W, Qian H, Jiang C.

Bioorg Med Chem. 2019 Jun 6. pii: S0968-0896(19)30775-8. doi: 10.1016/j.bmc.2019.06.013. [Epub ahead of print]

PMID:
31202598
3.

Wedelolactone alleviates doxorubicin-induced inflammation and oxidative stress damage of podocytes by IκK/IκB/NF-κB pathway.

Zhu MM, Wang L, Yang D, Li C, Pang ST, Li XH, Li R, Yang B, Lian YP, Ma L, Lv QL, Jia XB, Feng L.

Biomed Pharmacother. 2019 Jun 12;117:109088. doi: 10.1016/j.biopha.2019.109088. [Epub ahead of print]

PMID:
31202173
4.

Multifunctional PEG-b-polypeptide-decorated gold nanorod for targeted combined chemo-photothermal therapy of breast cancer.

Hou G, Qian J, Xu W, Sun T, Wang J, Wang Y, Suo A.

Colloids Surf B Biointerfaces. 2019 May 12;181:602-611. doi: 10.1016/j.colsurfb.2019.05.025. [Epub ahead of print]

PMID:
31202131
5.

Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification.

Cornillie J, Wozniak A, Li H, Gebreyohannes YK, Wellens J, Hompes D, Debiec-Rychter M, Sciot R, Schöffski P.

Clin Transl Oncol. 2019 Jun 14. doi: 10.1007/s12094-019-02158-z. [Epub ahead of print]

PMID:
31201607
6.

Chondrosarcoma of right big toe with metastases to left orbital and left infra temporal region.

Rafi M, Abbas S, Intakhab B, Shehzad A, Sultan G, Ahmed S, Maqbool A, Mohsin R, Bhutto K, Mubarak M, Hashmi A, Rizvi AUH.

J Pak Med Assoc. 2019 Jun;69(6):896-898.

7.

18F-FDG-PET dissemination features in diffuse large B cell lymphoma are prognostic of outcome.

Cottereau AS, Nioche C, Dirand AS, Clerc J, Morschhauser F, Casasnovas O, Meignan MA, Buvat I.

J Nucl Med. 2019 Jun 14. pii: jnumed.119.229450. doi: 10.2967/jnumed.119.229450. [Epub ahead of print]

PMID:
31201248
8.

Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.

Tabchi S, Nair R, Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Ahmed S, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian R, Feng L, Manasanch EE.

Clin Lymphoma Myeloma Leuk. 2019 May 17. pii: S2152-2650(19)30297-6. doi: 10.1016/j.clml.2019.05.001. [Epub ahead of print]

PMID:
31201134
9.

Integrated Analysis of Clinical and Microbiome Risk Factors Associated with the Development of Oral Candidiasis during Cancer Chemotherapy.

Diaz PI, Hong BY, Dupuy AK, Choquette L, Thompson A, Salner AL, Schauer PK, Hegde U, Burleson JA, Strausbaugh LD, Peterson DE, Dongari-Bagtzoglou A.

J Fungi (Basel). 2019 Jun 13;5(2). pii: E49. doi: 10.3390/jof5020049.

10.

Design, synthesis and anticervical cancer activity of new benzofuran-pyrazol-hydrazono- thiazolidin-4-one hybrids as potential EGFR inhibitors and apoptosis inducing agents.

Abbas HS, Abd El-Karim SS.

Bioorg Chem. 2019 Jun 4;89:103035. doi: 10.1016/j.bioorg.2019.103035. [Epub ahead of print]

PMID:
31200286
11.

The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model.

Miyake K, Higuchi T, Oshiro H, Zhang Z, Sugisawa N, Park JH, Razmjooei S, Katsuya Y, Barangi M, Li Y, Nelson SD, Murakami T, Homma Y, Hiroshima Y, Matsuyama R, Bouvet M, Chawla SP, Singh SR, Endo I, Hoffman RM.

Biomed Pharmacother. 2019 Jun 11;117:109093. doi: 10.1016/j.biopha.2019.109093. [Epub ahead of print]

PMID:
31200257
12.

SESN2 protects against doxorubicin-induced cardiomyopathy via rescuing mitophagy and improving mitochondrial function.

Wang P, Wang L, Lu J, Hu Y, Wang Q, Li Z, Cai S, Liang L, Guo K, Xie J, Wang J, Lan R, Shen J, Liu P.

J Mol Cell Cardiol. 2019 Jun 11. pii: S0022-2828(19)30128-2. doi: 10.1016/j.yjmcc.2019.06.005. [Epub ahead of print]

PMID:
31199952
13.

Microfluidic-Assisted Engineering of Quasi-Monodisperse pH-Responsive Polymersomes toward Advanced Platforms for the Intracellular Delivery of Hydrophilic Therapeutics.

Albuquerque LJC, Sincari V, Jäger A, Konefał R, Pánek J, Černoch P, Pavlova E, Štěpánek P, Giacomelli FC, Jäger E.

Langmuir. 2019 Jun 14. doi: 10.1021/acs.langmuir.9b01009. [Epub ahead of print]

PMID:
31199159
14.
15.

Photo-Fenton-like Metal-Protein Self-Assemblies as Multifunctional Tumor Theranostic Agent.

Li T, Zhou J, Wang L, Zhang H, Song C, de la Fuente JM, Pan Y, Song J, Zhang C, Cui D.

Adv Healthc Mater. 2019 Jun 13:e1900192. doi: 10.1002/adhm.201900192. [Epub ahead of print]

PMID:
31197956
16.

Prognostic implication of adjuvant/neoadjuvant chemotherapy consisting of doxorubicin and ifosfamide in patients with extraskeletal osteosarcoma.

Wakamatsu T, Kakunaga S, Takenaka S, Outani H, Hamada K, Imura Y, Hori Y, Naka N, Kudawara I, Yoshikawa H, Ueda T.

Int J Clin Oncol. 2019 Jun 13. doi: 10.1007/s10147-019-01475-1. [Epub ahead of print]

PMID:
31197555
17.

Bio-inspired drug-dominated supramolecular nanocomplex based on low molecular weight heparin for progressive tumor therapy.

Yu Y, Xu C, Zhen L, Yang S, Zhou J, Yao J.

Carbohydr Polym. 2019 Sep 15;220:30-42. doi: 10.1016/j.carbpol.2019.05.051. Epub 2019 May 15.

PMID:
31196548
18.

Synthesis of folate mediated carboxymethyl cellulose fatty acid ester and application in drug controlled release.

Li J, Yang J.

Carbohydr Polym. 2019 Sep 15;220:126-131. doi: 10.1016/j.carbpol.2019.05.052. Epub 2019 May 17.

PMID:
31196531
19.

Bioinspired Drug Delivery Carrier for Enhanced Tumor-Targeting in Melanoma Mice Model.

Wang X, Liang GF, Hao XQ, Feng SY, Dai L, An JL, Li JH, Shi H, Feng WP, Zhang X.

J Biomed Nanotechnol. 2019 Jul 1;15(7):1482-1491. doi: 10.1166/jbn.2019.2786.

PMID:
31196352
20.

Multifunctional A7R Peptide-Modified Hollow Mesoporous Silica@Ag₂S Nanotheranostics for Photoacoustic/Near-Infrared Fluorescence Imaging-Guided Tumor-Targeted Chemo-Photothermal Therapy.

Wu J, Bremner DH, Niu S, Li D, Tang R, Zhu LM.

J Biomed Nanotechnol. 2019 Jul 1;15(7):1415-1431. doi: 10.1166/jbn.2019.2729.

PMID:
31196347

Supplemental Content

Loading ...
Support Center